{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:53:09Z","timestamp":1780365189833,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.amjmed.2020.04.006","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:30:53Z","timestamp":1588825853000},"page":"e625-e630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4797-1165","authenticated-orcid":false,"given":"Kris","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1747-2859","authenticated-orcid":false,"given":"Babikir","family":"Kheiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8580-0773","authenticated-orcid":false,"given":"Timothy F.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2020.04.006_bib0001","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0735-1097(01)01408-5","article-title":"Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction","volume":"38","author":"Dries","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0002","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovic","year":"2018","journal-title":"Eur J Heart Failure"},{"issue":"2","key":"10.1016\/j.amjmed.2020.04.006_bib0003","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose cotransporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0004","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on the developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0005","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0006","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2020.04.006_bib0007","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0008","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Eng J Med"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0009","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"sodium glucose cotransporter-2 inhibition in heart failure \u2013 potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation."},{"issue":"18","key":"10.1016\/j.amjmed.2020.04.006_bib0011","first-page":"1463-1476","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"140","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms and functional status in patients with heart failure with reduced ejection fraction: The DEFINE-HF Trial","author":"Nassif","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjmed.2020.04.006_bib0013","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"10166","key":"10.1016\/j.amjmed.2020.04.006_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.amjmed.2020.04.006_bib0015","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0016","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review","volume":"72","author":"Zelniker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","article-title":"Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials","volume":"54","author":"Monami","year":"2017","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0018","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0019","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation."},{"issue":"10","key":"10.1016\/j.amjmed.2020.04.006_bib0020","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state of the art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2020.04.006_bib0021","unstructured":"ClinicalTrials.gov. NCT03619213: Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure (DELIVER). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619213. Accessed March 3, 2020."},{"issue":"24","key":"10.1016\/j.amjmed.2020.04.006_bib0022","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","volume":"72","author":"Das","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320303612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320303612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:20:49Z","timestamp":1757582449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934320303612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0002934320303612"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.04.006","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}